← All trials
NCT07167342
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Oct 31, 2029
- Completion date
- Oct 31, 2030
- First posted
- Sep 11, 2025
- Last posted
- Sep 11, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qingdao UniversityLead sponsor
- Qingdao UniversityCollaborator
- Shandong UniversityCollaborator
- Shandong UniversityCollaborator
- Qingdao UniversityOfficial
- People's Hospital of RizhaoCollaborator
- Shandong Provincial HospitalCollaborator
- Tai'an Central HospitalCollaborator
- Linyi People's HospitalCollaborator
- Shandong Province Qianfoshan HospitalCollaborator
- Weifang People's HospitalCollaborator
- Jining NO.1 People 's HospitalCollaborator
- Qingdao UniversitySponsor investigator
- Dongying People's Hospital, ShandongCollaborator
- Shandong first medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.